Author: Weiss Johanna Theile Dirk Dvorak Zdenek Haefeli Walter Emil
Publisher: MDPI
E-ISSN: 1999-4923|6|4|632-650
ISSN: 1999-4923
Source: Pharmaceutics, Vol.6, Iss.4, 2014-12, pp. : 632-650
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Dovitinib (TKI-258) is under development for the treatment of diverse cancer entities. No published information on its pharmacokinetic drug interaction potential is available. Thus, we assessed its interaction with important drug metabolising enzymes and drug transporters and its efficacy in multidrug resistant cells
Related content
By Paletta-Silva Rafael Rocco-Machado Nathália Meyer-Fernandes José Roberto
International Journal of Molecular Sciences, Vol. 14, Iss. 2, 2013-02 ,pp. :
By Quan Jinhua Yahata Tetsuro Adachi Sosuke Yoshihara Kosuke Tanaka Kenichi
International Journal of Molecular Sciences, Vol. 12, Iss. 2, 2011-01 ,pp. :
By Ono Masahiro Baden Atsumi Okudaira Hiroyuki Kobayashi Masato Kawai Keiichi Oka Shuntaro Yoshimura Hirokatsu
International Journal of Molecular Sciences, Vol. 17, Iss. 10, 2016-10 ,pp. :
Role of Receptor Tyrosine Kinase Signaling in Renal Fibrosis
International Journal of Molecular Sciences, Vol. 17, Iss. 6, 2016-06 ,pp. :